Evaxion A/S

Evaxion A/S (EVAX) priced its initial public offering on Feb 5, 2021 at $10.00 per ADS, within its $10.00–$12.00 range, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $192M. Oppenheimer was lead-left underwriter, joined by Ladenburg Thalmann. Duane Morris advised the company and Mintz advised the underwriters.

Evaxion A/S is a clinical-stage company using proprietary artificial intelligence to simulate the human immune system and build predictive models that identify and develop immunotherapies for cancers, bacterial diseases and viral infections. It calls its approach AI-immunology.

Status

IPO

Ticker

EVAX

Exchange

Nasdaq Capital Market

Priced

Feb 5, 2021

IPO price

$10.00 per ADS

Price range

$10.00–$12.00

Market cap at IPO price

$192M

First filed

Jan 8, 2021

Underwriters

Oppenheimer and Ladenburg Thalmann

Company counsel

Duane Morris

Underwriters' counsel

Mintz

Sector

Biotech & pharma

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.